Total Burden of Events: A New Standard Stressing the Positive Impact of Inflammation Modulation

Affiliations

¹ PhyMedExp, Université de Montpellier, INSERM, CNRS, Cardiology Department, CHU de Montpellier, Montpellier, France. Electronic address: francois.roubille@gmail.com.
² PhyMedExp, Université de Montpellier, INSERM, CNRS, Cardiology Department, CHU de Montpellier, Montpellier, France.
³ Clinical Research and Epidemiology Unit, CHU Montpellier, Université de Montpellier, Montpellier, France; CEPEL, Université de Montpellier, CNRS, Montpellier, France.

Free article

Editorial

François Roubille et al. J Am Coll Cardiol. 2020.

Free article

. 2020 Oct 6;76(14):1671-1673.

doi: 10.1016/j.jacc.2020.08.036.

¹ PhyMedExp, Université de Montpellier, INSERM, CNRS, Cardiology Department, CHU de Montpellier, Montpellier, France. Electronic address: francois.roubille@gmail.com.
² PhyMedExp, Université de Montpellier, INSERM, CNRS, Cardiology Department, CHU de Montpellier, Montpellier, France.
³ Clinical Research and Epidemiology Unit, CHU Montpellier, Université de Montpellier, Montpellier, France; CEPEL, Université de Montpellier, CNRS, Montpellier, France.

No abstract available

Keywords: canakinumab; colchicine; coronary artery disease; inflammation; negative binomial regression; recurrent events.

Comment on

Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial.
Everett BM, MacFadyen JG, Thuren T, Libby P, Glynn RJ, Ridker PM. Everett BM, et al. J Am Coll Cardiol. 2020 Oct 6;76(14):1660-1670. doi: 10.1016/j.jacc.2020.08.011. J Am Coll Cardiol. 2020. PMID: 33004131 Clinical Trial.